Nasdaq

FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

WESTLAKE VILLAGE, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...
News Medical

Skin rashes more common in adults tested positive for COVID-19

Previous studies conducted in hospitals reported that COVID-19 patients presented with unusual skin rashes. This study, which is published in the British Journal of Dermatology, analyzed information ...
Medical News Today

Seborrheic dermatitis affecting the chest: What to know

Seborrheic dermatitis is an inflammatory condition leading to scaly skin rashes. It can appear on many areas of the body, including the chest. While it can affect people of any age, it is most common ...
Nasdaq

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and ...

WESTLAKE VILLAGE, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...